<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03384212</url>
  </required_header>
  <id_info>
    <org_study_id>2016-22</org_study_id>
    <nct_id>NCT03384212</nct_id>
  </id_info>
  <brief_title>CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML</brief_title>
  <official_title>CBA Versus FBA Conditioning Followed by Allogeneic HSCT in Treatment of High Risk and Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chengdu PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tang-Du Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: To evaluated if cladribine based conditioning (CBA) could decrease relapse after HLA
      matched HSCT in high risk and refractory AML patients as compared with fludarabine based
      conditioning regimen(FBA).

      Study design: open-labed, prospective, multicenter, randomized control study Number of
      subjects: 60 each group

      Treatment:

      CBA group: CBA as HSCT conditioning which including cladribine 5mg/m2 day -6 to day -2 ,
      busulfan(iv) 3.2mg/kg day-6 to day -3 and cytarabine 2g/m2 day-6 to day -2.

      FBA group: FBA as HSCT conditioning which including fludarabine 30mg/m2 day -6 to day -2,
      busulfan(iv) 3.2mg/kg day-6 to day -3 and cytarabine 2g/m2 day-6 to day -2.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Relapse is still the main reason of death for patients with acute myeloid leukemia (AML)
      undergoing allogeneic hematopoietic stem cell transplantation (HSCT), especially for those
      with high risk and refractory disease. Cladribine and fludarabine are both purine analogs
      used in treatment of AML. Two studies by the Polish Adult Leukemia Group (PALG) demonstrated
      that the addition of cladribine to DA (DAC) was associated with an increased complete
      remission (CR) rate and prolonged overall survival (OS) in the general AML population, with
      the most prominent effect in patients with unfavorable cytogenetics. Therefore we presume
      cladribine may more effective in eliminating leukemic cells so that reduce relapse after
      HSCT.

      Eligible patients in this study should between 18 to 60 years old with confirmed AML and
      fulfilled at least one criteria defining high risk or refractory disease.Patients must have
      HLA 9/10 or 10/10 matched sibling or unrelated donor. Patients will be excluded if they
      present any contraindication for HSCT, including respiratory failure, heart failure, liver or
      kidney function failure et al.

      To evaluate if cladribine based conditioning (CBA) could decrease relapse after HLA matched
      HSCT in high risk and refractory AML patients as compared with fludarabine based conditioning
      regimen(FBA), 120 eligible patients will be randomized to two groups, the CBA group and the
      FBA group. Patients in the CBA group receive conditioning including cladribine 5mg/m2 day -6
      to day -2 , busulfan(iv) 3.2mg/kg day-6 to day -3 and cytarabine 2g/m2 day-6 to day -2. While
      patients in the FBA group receive conditioning including fludarabine 30mg/m2 day -6 to day -2
      , busulfan(iv) 3.2mg/kg day-6 to day -3 and cytarabine 2g/m2 day-6 to day -2. Graft versus
      host disease(GVHD) prophylactic regimen include cyclosporine A and short term MTX, ATG 6mg/kg
      is additionally administered to patients with unrelated donors.

      Patients will be followed up for 2 years and the primary end point is the cumulative relapse
      rate at 2 years. The second end points of the study include the overall survival, disease
      free survival and non-relapse mortality at 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2016</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open labled randomized controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative relapse rate at 2 year</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of all patients who are relapsed within 2 years after allogeneic HSCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival at 2 year</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of all patients who are still alive 2 years after allogeneic HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival at 2year</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of all patients who are leukemia free 2 years after allogeneic HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality at 2year</measure>
    <time_frame>2 years</time_frame>
    <description>The percentage of patients who are dead of all reasons except relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality at 100days</measure>
    <time_frame>100 days</time_frame>
    <description>The percentage of patients who are dead of all reasons except relapse.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>High Risk Acute Myeloid Leukemia</condition>
  <condition>Allogeneic Hematopoeitic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>CBA group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBA as HSCT conditioning:
cladribine 5mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FBA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FBA as HSCT conditioning:
fludarabine 30mg/m2 day -6 to day -2 busulfan(iv) 3.2mg/kg day-6 to day -3 cytarabine 2g/m2 day-6 to day -2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <arm_group_label>CBA group</arm_group_label>
    <other_name>chlorodeoxyadenosine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <arm_group_label>FBA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Busulfan</intervention_name>
    <arm_group_label>CBA group</arm_group_label>
    <arm_group_label>FBA group</arm_group_label>
    <other_name>busulphan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>CBA group</arm_group_label>
    <arm_group_label>FBA group</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of AML confirmed by bone marrow cell morphology, immunology, cytogenetics
             and molecular biology (MICM). Blast crisis of chronic myeloid leukemia (CML) and AML
             transferred from myelodysplastic syndrome(MDS) or other diseases are also included.

          2. AML with high risk cytogenetic abnormals, such as FLT3- ITD, et al.

          3. Patients fulfilled at least one of the following criteria defining refractory AML:(1)
             primary induction failure (PIF) after 2 or more cycles of chemotherapy; (2) first
             early relapse after a remission duration of fewer than 12 months and refractory to
             salvage combination chemotherapy; (3) second or subsequent relapse .

          4. Have HLA 9/10 or 10/10 matched siblings or unrelated donor，the donor must match the
             health conditions of hematopoietic stem cell donation (criteria of China Marrow Donor
             Program) and be willing to donate.

          5. Performance status score no more than 2 (ECOG criteria).

          6. Adequate organ function as defined by the following criteria:ALT, AST and total serum
             bilirubin &lt;2×ULN (upper limit of normal), Serum creatinine and BUN &lt;1.25×ULN.

          7. Adequate cardiac function without acute myocardial infarction, arrhythmia or
             atrioventricular block, heart failure, active rheumatic heart disease and cardiac
             dilatation.

          8. Signed and dated informed consent document indicating that the patient (or legally
             acceptable representative) has been informed of all pertinent aspects of the trial
             prior to enrollment.

          9. Willingness and ability to comly with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

        Exclusion Criteria:

          1. Presence of any condition inappropriate for HSCT.

          2. Presence of any fatal disease, including respiratory failure, heart failure, liver or
             kidney function failure et al.

          3. Have no suitable donor.

          4. Pregnancy or breast feeding.

          5. Current treatment on another clinical trail.

          6. Any other condition the investigator judged the patient inappropriate for entry into
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chun Wang, M.D.,Ph. D.</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai general hospital, Shanghai Jiaotong university school of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jieling Jiang, M.D.</last_name>
    <phone>86-21-37798987</phone>
    <email>jiangjieling66@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liping Wan, M.D., Ph.D.</last_name>
    <phone>86-21-37798987</phone>
    <email>wanliping924@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai general hospital, Shanghai Jiaotong university school of medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingpeng Wang, M.D.,Ph. D.</last_name>
      <phone>86-21-63069298</phone>
      <email>sfph_edu2@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yanhong Zhu</last_name>
      <phone>86-21-63240090</phone>
      <phone_ext>6213</phone_ext>
      <email>sfph_edu2@shumu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Jieling Jiang, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xiaoxia Hu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Qiang Liu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yajing Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ting Yang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Huangfang Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang Cao, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Holowiecki J, Grosicki S, Robak T, Kyrcz-Krzemien S, Giebel S, Hellmann A, Skotnicki A, Jedrzejczak WW, Konopka L, Kuliczkowski K, Zdziarska B, Dmoszynska A, Marianska B, Pluta A, Zawilska K, Komarnicki M, Kloczko J, Sulek K, Haus O, Stella-Holowiecka B, Baran W, Jakubas B, Paluszewska M, Wierzbowska A, Kielbinski M, Jagoda K; Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. Leukemia. 2004 May;18(5):989-97.</citation>
    <PMID>14999298</PMID>
  </reference>
  <reference>
    <citation>Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O. Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol. 2012 Jul 10;30(20):2441-8. doi: 10.1200/JCO.2011.37.1286. Epub 2012 Apr 16.</citation>
    <PMID>22508825</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2017</study_first_posted>
  <last_update_submitted>December 23, 2017</last_update_submitted>
  <last_update_submitted_qc>December 23, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Chun Wang</investigator_full_name>
    <investigator_title>director, department of hematology</investigator_title>
  </responsible_party>
  <keyword>cladribine</keyword>
  <keyword>fludarabine</keyword>
  <keyword>relapse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cladribine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

